Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Wellbutrin XL Approval Pressures Generics to Launch SR Formulation

Executive Summary

The approval of GlaxoSmithKline's Wellbutrin XL puts pressure on generic firms to launch their sustained-release versions of the antidepressant

You may also be interested in...



GSK Wellbutrin Metabolite, Advair Successor In Phase II; NDAs In 2006-2008

GlaxoSmithKline expects to bring a Wellbutrin (bupropion) metabolite into Phase III studies for major depressive disorder during the second half of 2004

GSK Wellbutrin Metabolite, Advair Successor In Phase II; NDAs In 2006-2008

GlaxoSmithKline expects to bring a Wellbutrin (bupropion) metabolite into Phase III studies for major depressive disorder during the second half of 2004

Eon Wellbutrin SR Generic Launch Could Slow GSK Conversion Efforts

Eon's launch of generic bupropion extended-release (Wellbutrin SR) should allow it to grab significant market share before GlaxoSmithKline fully converts SR patients to once-daily Wellbutrin XL

Related Content

UsernamePublicRestriction

Register

PS042395

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel